ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

GAO Says Multiple Year Funding Not Legal; Weicker Demands Assurance That Administration Will Comply

March 29, 1985

Finasteride For Prostate Cancer Prevention Causes Little Or No Sexual Dysfunction

August 31, 2007

In Brief: Proposed Drug Act Revisions Would Provide Quick Approval Of “Breakthroughs,” IND_NDA Changes

March 24, 1978

In Brief: alberts elected To Second Term as NAS President

February 19, 1999

UFT – Leucovorin Combo Not A Breakthrough, But could Merit Approval, Committee Says

September 24, 1999

National Dialogue On Cancer, The Cancer Act, And Activism.

February 4, 2000